Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMABRXY)

• Drug Name: IDM-2101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMABRXY

Molecule-Related Drug Atlas

Drug(s) Targeting Carcinoembryonic antigen CEA (CD66e)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR408701	DMXGE3O	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
Tusamitamab ravtansine	DMMPSA1	Non-small-cell lung cancer	2C25	Phase 3	[3]
CAP1-6D	DMEYIVW	Pancreatic cancer	2C10	Phase 2	[4]
Pentacea	DMGY5JC	Small-cell lung cancer	2C25.Y	Phase 2	[5]
GI-6207	DM72O6F	Thyroid cancer	2D10	Phase 2	[6]
CeaVac	DM6Z9BV	Colorectal cancer	2B91.Z	Phase 2	[7]
Labetuzumab I-131	DMNO5UE	Colorectal cancer	2B91.Z	Phase 2	[8]
AVX701	DMOPVIQ	Colorectal cancer	2B91.Z	Phase 1/2	[9]
CT84.66	DM6078F	Breast cancer	2C60-2C65	Phase 1/2	[10]
CAR-T cells targeting CEA	DM6VCPX	Colorectal cancer	2B91.Z	Phase 1/2	[11]

Drug(s) Targeting Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Astuprotimut-R	DMLY0H5	Non-small-cell lung cancer	2C25.Y	Phase 3	[12]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[13]
GL-0817	DM17OZM	Head and neck cancer	2D42	Phase 2	[14]
KITE-718	DMBSI6Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Not Available	[1]
Melanoma-associated antigen 3 (MAGEA3)	TTWSKHD	MAGA3_HUMAN	Not Available	[1]

References

• [1] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [2] ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [3] Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
• [4] Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
• [5] Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
• [6] Clinical pipeline report, company report or official report of GlobeImmune.
• [7] Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
• [8] National Cancer Institute Drug Dictionary (drug id 692828).
• [9] Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
• [10] Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
• [11] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• [12] National Cancer Institute Drug Dictionary (drug id 600553).
• [13] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
• [16] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.